Another study showed that for NSCLC patients (PD-L1 expression ≥5%), median PFS was 4.2 months for patients treated with PD-1 antibody nivolumab and 5.9 months for patients treated with chemotherapy [9]. Here, CD274 is linked to non-small cell lung carcinoma.